OCT Evaluation of Healing of COMBO Stent (EGO-COMBO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Prof. Stephen Lee, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT01274234
First received: December 28, 2010
Last updated: February 27, 2013
Last verified: February 2013
  Purpose

All subjects requiring percutaneous coronary intervention (PCI) and stenting are eligible to participate in the study. Restudy coronary angiogram with Optical Coherence Tomography (OCT) would be performed between 1 to 5 months at the time of a staged PCI procedure (for remaining coronary disease) or as clinically indicated, and then at 9 months. At the time of the 9-month restudy (a proper time window for drug eluting stent to develop into restenosis should it occur), any new disease detected or restenosis will be treated. The reported incidence of drug eluting stent restenosis is around 10% in simple lesions and is expected to be higher in diabetic patients, long lesions and multi-vessel diseases; a restudy at 9 months actually confers better protection to the patients with advanced disease and any restenosis can be treated timely. All data on clinical events and progress will be monitored and regular follow-ups will be carried out.


Condition Intervention Phase
Coronary Restenosis
Coronary Thrombosis
Device: COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study

Resource links provided by NLM:


Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • Primary end-point: OCT findings on percentage stent strut coverage in the 2nd to the 5th months (4 monthly groups). [ Time Frame: On 2nd, 3rd, 4th, and 5th months ] [ Designated as safety issue: No ]
    Primary end-point: OCT findings on percentage stent strut coverage, malapposition, and neointimal thickness in the 2nd to the 5th months (4 monthly groups).


Secondary Outcome Measures:
  • OCT findings on late loss (neointimal thickness and neointimal area) at 9 months restudy. [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    OCT findings on late loss (neointimal thickness, neointimal area, percentage plaque volume, lumen area, and late loss in lumen area) at 9 months restudy.

  • Major Adverse Cardiac Events [ Time Frame: Initial OCT follow up, 9 months follow up and one year follow up ] [ Designated as safety issue: No ]

    Major Adverse Cardiac Events (MACE) which defined as:

    1. Death from all cause including cardiac death
    2. Any Myocardial Infarction (Q wave and non Q-wave)

    Elevation of post-procedure CK levels to greater 2 times normal without new Q waves is considered a non Q-wave MI.

    Development of new, pathological Q waves in 2 or more contiguous leads,as assessed by the investigator and confirmed by the Clinical Endpoint Committee and elevation of cardiac enzymes. In the absence of ECG data the CEC may adjudicate Q wave MI based on the clinical scenario and appropriate cardiac enzyme data.


  • Major Adverse Cardiac Events [ Time Frame: Initial OCT follow up, 9 months OCT follow up and one year follow up ] [ Designated as safety issue: No ]
    3. Target Lesion Revascularization requiring repeat PCI or CABG to the target lesion. Clinically driven Revascularization at the target lesion associated with positive functional ischemia study or ischemic symptoms AND an angiographic minimal lumen diameter stenosis ≥50% by QCA, or revascularization of a target lesion with diameter stenosis ≥ 70% by QCA without either angina or a positive functional study.

  • Any Stent Thrombosis according the Academic Research Consortium [ Time Frame: Initial OCT follow up, 9 months OCT follow up and one year follow up ] [ Designated as safety issue: No ]
  • Stroke [ Time Frame: Initial OCT follow up, 9 months OCT follow up and one year follow up ] [ Designated as safety issue: No ]
    Stroke defined as sudden onset of vertigo, numbness, dysphasia, weakness, visual field defects, dysarthria or other focal neurological deficits due to vascular lesions of the brain such as hemorrhage, embolism, thrombosis, or rupturing aneurysm, that persists more than 24 hours.

  • Bleeding complication [ Time Frame: Initial OCT follow up, 9 months OCT follow up and one year follow up ] [ Designated as safety issue: No ]
    Bleeding complication defined as a procedure related hemorrhagic event that requires a transfusion or surgical repair. These may include a hematoma requiring treatment of retroperitoneal bleed.


Enrollment: 61
Study Start Date: October 2010
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: COMBO Stent
COMBO Stent
Device: COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)
The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
Other Name: COMBO Stent

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patient aged 18-85 years old,
  • patient with coronary stenosis requiring percutaneous coronary intervention without contraindications to implantation of drug eluting stents
  • patient who consents to receive follow-up coronary angiogram and OCT examination.

Exclusion Criteria:

- patient who refuses to consent to follow-up coronary angiogram or OCT examination.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01274234

Locations
Hong Kong
Division of Cardiology, Queen Mary Hospital, The University of Hong Kong
Hong Kong, Hong Kong
Sponsors and Collaborators
Prof. Stephen Lee
Investigators
Principal Investigator: Stephen Lee, MD FRCP FACC Queen Mary Hospital, The Unversity of Hong Kong
  More Information

Publications:

Responsible Party: Prof. Stephen Lee, Professor and Chief, The University of Hong Kong
ClinicalTrials.gov Identifier: NCT01274234     History of Changes
Other Study ID Numbers: UW 10-342 (IRB HKU)
Study First Received: December 28, 2010
Last Updated: February 27, 2013
Health Authority: Hong Kong: Ethics Committee

Keywords provided by The University of Hong Kong:
EPC capturing sirolimus eluting COMBO stent
Optical coherence tomography (OCT)
Early neointimal healing and stent coverage
Late neointimal thickness, neointimal area, and lumen loss

Additional relevant MeSH terms:
Coronary Thrombosis
Thrombosis
Coronary Restenosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Embolism and Thrombosis
Vascular Diseases
Coronary Stenosis
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 26, 2014